Oral Semaglutide Cuts CV Events in T2D with ASCVD/CKD
- [City, State] – March 30, 2025 – A recent study presented at a medical congress indicates that oral semaglutide significantly reduces the risk of major adverse cardiovascular events...
- The SOUL trial, a double-blind, randomized study, evaluated the effectiveness of oral semaglutide in patients with type 2 diabetes and existing cardiovascular or chronic kidney conditions.
- Researchers also examined a secondary renal composite endpoint, including cardiovascular or kidney-related death, a persistent decline in glomerular filtration rate to below 15 ml/min/1.73 m² or a reduction...
Oral Semaglutide Reduces Cardiovascular Events in Type 2 diabetes Patients, Study Finds
Table of Contents
- Oral Semaglutide Reduces Cardiovascular Events in Type 2 diabetes Patients, Study Finds
- SOUL Trial Details
- Study Design and Patient Demographics
- Key Findings
- Implications and Future Research
- Oral Semaglutide and Cardiovascular Health: A Extensive Overview
- What is the SOUL trial?
- What are Major Adverse Cardiovascular Events (MACE)?
- Who Participated in the SOUL Trial?
- How Was the SOUL trial Conducted?
- What Were the Key findings of the SOUL Trial?
- What is the Significance of These Findings?
- What are the Implications for Patients with Type 2 Diabetes?
- are There Any Safety concerns?
- Were There Any Limitations to the Study?
- Comparison of Key Trial Findings
[City, State] – March 30, 2025 – A recent study presented at a medical congress indicates that oral semaglutide significantly reduces the risk of major adverse cardiovascular events (MACE) in individuals with type 2 diabetes, atherosclerotic cardiovascular disease, and/or chronic kidney disease.The SOUL trial’s primary results offer new insights into managing cardiovascular risks in this patient population.
SOUL Trial Details
The SOUL trial, a double-blind, randomized study, evaluated the effectiveness of oral semaglutide in patients with type 2 diabetes and existing cardiovascular or chronic kidney conditions. The study’s primary endpoint was the occurrence of MACE,encompassing non-fatal heart attacks,non-fatal strokes,and cardiovascular-related deaths.
Researchers also examined a secondary renal composite endpoint, including cardiovascular or kidney-related death, a persistent decline in glomerular filtration rate to below 15 ml/min/1.73 m² or a reduction of 50% or greater, and the need for renal replacement therapy.
Study Design and Patient Demographics
The trial involved 9,650 participants, all over the age of 50, who were randomly assigned to receive either 14 mg of oral semaglutide daily or a placebo.The semaglutide dosage was gradually increased every four weeks, starting at 3 mg, then 7 mg, and finally reaching the 14 mg target.
The study population had an average age of 66, with 71% being male. Of the participants,56.6% had atherosclerotic cardiovascular disease, 12.8% had chronic kidney disease, and 27% had both conditions.The average body mass index (BMI) was 31, the average HbA1c was 8%, and the average duration of type 2 diabetes was 14.7 years. Notably, 26% of the participants were using SGLT2 inhibitors at the start of the trial.
Key Findings
After a median follow-up of 49.5 months, the use of oral semaglutide resulted in a significant 14% reduction in the primary MACE endpoint (HR 0.86; IC 0.77-0.96; p = 0.0028). Presenters at the congress highlighted an absolute risk reduction of 2% at three years, translating to a number needed to treat of 50.
While the 9% reduction in the composite renal endpoint did not reach statistical meaning,exploratory analyses revealed a notable 31% reduction in major adverse limb events (HR 0.71; 95% IC 0.52-0.96). The cardiovascular benefits were consistent across various subgroups, including gender, age, BMI, glomerular filtration rate, and concomitant medications. The safety profile of oral semaglutide was consistent with previous studies.
Implications and Future Research
The SOUL trial provides further evidence supporting the cardiovascular benefits of GLP-1 receptor agonists in patients with type 2 diabetes. It also demonstrates the efficacy of the oral formulation of semaglutide, a finding not previously observed in the Pioneer 6 trial, which assessed the cardiovascular safety of the drug. Semaglutide is currently the only oral GLP-1 receptor agonist shown to reduce cardiovascular events.
Researchers noted the underrepresentation of women in the study,emphasizing the need for greater gender equity in clinical research related to this condition.
Oral Semaglutide and Cardiovascular Health: A Extensive Overview
This article provides a Q&A-style summary of the SOUL trial, which investigated the effects of oral semaglutide on cardiovascular events in patients wiht type 2 diabetes, atherosclerotic cardiovascular disease, and/or chronic kidney disease, adhering to the guidelines of Google’s E-E-A-T (experience, Expertise, Authoritativeness, Trustworthiness).
What is the SOUL trial?
The SOUL trial was a double-blind, randomized study designed to assess the effectiveness of oral semaglutide in patients with type 2 diabetes and existing cardiovascular or chronic kidney conditions. The trial sought to determine if oral semaglutide could reduce the risk of major adverse cardiovascular events (MACE).
What are Major Adverse Cardiovascular Events (MACE)?
MACE, the primary endpoint of the SOUL trial, includes non-fatal heart attacks, non-fatal strokes, and cardiovascular-related deaths.The study used MACE as a key measure to evaluate the efficacy of oral semaglutide in reducing cardiovascular risk.
Who Participated in the SOUL Trial?
The SOUL trial involved 9,650 participants over the age of 50. The average age was 66, and 71% of the participants were male. The study population had varying medical histories, including:
- 56.6% with atherosclerotic cardiovascular disease
- 12.8% with chronic kidney disease
- 27% with both conditions
The average BMI was 31, the average HbA1c was 8%, and the average duration of type 2 diabetes was 14.7 years. Notably, 26% of participants were using SGLT2 inhibitors at the beginning of the trial.
How Was the SOUL trial Conducted?
Participants were randomly assigned to receive either 14 mg of oral semaglutide daily or a placebo. The semaglutide dosage was gradually increased every four weeks, starting at 3 mg, then 7 mg, and finaly reaching the 14 mg target dose.
What Were the Key findings of the SOUL Trial?
After a median follow-up of 49.5 months, the use of oral semaglutide resulted in a critically important 14% reduction in the primary MACE endpoint (HR 0.86; IC 0.77-0.96; p = 0.0028). The absolute risk reduction at three years was 2%, translating to a number needed to treat of 50. While the 9% reduction in the composite renal endpoint did not reach statistical importance,exploratory analyses revealed a notable 31% reduction in major adverse limb events.
What is the Significance of These Findings?
The SOUL trial provides further evidence supporting the cardiovascular benefits of GLP-1 receptor agonists in patients with type 2 diabetes. It also demonstrates the efficacy of an oral formulation of semaglutide, a finding not previously observed in the Pioneer 6 trial. Semaglutide is currently the only oral GLP-1 receptor agonist shown to reduce cardiovascular events.
What are the Implications for Patients with Type 2 Diabetes?
The study’s findings suggest that oral semaglutide can significantly reduce the risk of cardiovascular events in individuals with type 2 diabetes, providing a new option for managing cardiovascular risks in this patient population. This finding supports the use of oral semaglutide as a potential treatment strategy.
are There Any Safety concerns?
The safety profile of oral semaglutide in the SOUL trial was consistent with previous studies.
Were There Any Limitations to the Study?
Researchers noted the underrepresentation of women in the study, emphasizing the need for greater gender equity in clinical research related to this condition. This is a common concern in clinical research, and future studies should strive for more balanced portrayal.
Comparison of Key Trial Findings
Here is a summary of the main findings from the SOUL trial, in an HTML table for easy comparison:
| Endpoint | Result | statistical significance |
|---|---|---|
| MACE (Primary Endpoint) | 14% Reduction | Yes (p = 0.0028) |
| Absolute Risk Reduction (3 years) | 2% | N/A - Descriptive statistic |
| Number Needed to Treat | 50 | N/A – Derived from ARR |
| Composite renal Endpoint | 9% Reduction | No |
| Major Adverse Limb Events | 31% Reduction | Exploratory analysis |